Document:

Exhibit 10.8

Execution
Version

 

EMPLOYMENT
AGREEMENT

 

THIS EMPLOYMENT AGREEMENT
(this “Agreement”), entered into as of September 30, 2020, is made by and between Aziyo Biologics, Inc.
(the “Company”) and Thomas Englese (the “Executive”) (collectively referred
to herein as the “Parties”).

 

WHEREAS, the Executive
is currently employed by the Company as its Chief Commercial Officer pursuant to the terms of that certain Offer Letter by and
between the Parties, dated as of June 25, 2019 (the “Prior Agreement”);

 

WHEREAS, the Company
is contemplating an initial public offering of its Class A common stock pursuant to an effective registration statement filed
under the Securities Act of 1933, as amended (the “IPO”);

 

WHEREAS, in connection
with the IPO, the Company desires to assure itself of the continued services of the Executive by engaging the Executive to perform
services under the terms hereof;

 

WHEREAS, the Executive
desires to provide services to the Company on the terms herein provided; and

 

WHEREAS, the Parties
desire to have this Agreement become effective, and supersede the Prior Agreement, as the date of the consummation of the IPO (the
 “Effective Date”).

 

NOW, THEREFORE, IT
IS HEREBY AGREED AS FOLLOWS:

 

1.            Employment
Period. Subject to the provisions for earlier termination hereinafter provided, the initial term of the Executive’s employment
hereunder shall be for a term (the “Initial Employment Period”) commencing on the Effective Date and
ending on the second anniversary of the Effective Date. The Initial Employment Period shall automatically be extended for successive
one-year periods (each, an “Extension Employment Period” and, together with the Initial Employment Period,
the “Employment Period”), unless either Party gives written notice of non-extension to the other no later
than ninety (90) days prior to the expiration of the then-applicable Employment Period, in which case Executive’s employment
will terminate at the end of the then-applicable Employment Period, subject to earlier termination as provided in Section 4
below.

 

2.            Terms
of Employment.

 

(a)           Position
and Duties.

 

(i)            Role
and Responsibilities. During the Employment Period, the Executive shall serve as Chief Commercial Officer of the Company, and
shall perform such employment duties as are usual and customary for such positions. The Executive shall report directly to the
Chief Executive Officer of the Company (or his or her designee). At the Company’s request, the Executive shall serve the
Company and/or its subsidiaries and affiliates in other capacities in addition to the foregoing, consistent with the Executive’s
position as Chief Commercial Officer of the Company. In the event that the Executive, during the Employment Period, serves in any
one or more of such additional capacities, the Executive’s compensation shall not be increased beyond that specified in Section 2(b) hereof.
In addition, in the event the Executive’s service in one or more of such additional capacities is terminated, the Executive’s
compensation, as specified in Section 2(b) hereof, shall not be diminished or reduced in any manner as a result of such
termination provided that the Executive otherwise remains employed under the terms of this Agreement.

 

     

     

    

 

(ii)            Exclusivity.
During the Employment Period, and excluding any periods of vacation and sick leave to which the Executive may be entitled, the
Executive agrees to devote his or her full business time and attention to the business and affairs of the Company. Notwithstanding
the foregoing, during the Employment Period, it shall not be a violation of this Agreement for the Executive to: (A) serve
on boards, committees or similar bodies of charitable or nonprofit organizations or other companies, (B) fulfill limited teaching,
speaking and writing engagements, and (C) manage his or her personal investments, in each case, so long as such activities
do not individually or in the aggregate materially interfere or conflict with the performance of the Executive’s duties and
responsibilities under this Agreement; provided, that with respect to the activities in subclauses (A) and/or (B),
the Executive receives prior written approval from the Chief Executive Officer. Exhibit A of this Agreement sets forth
the board of directors or advisory boards on which the Executive currently serves.

 

(iii)           Principal
Location. During the Employment Period, the Executive shall perform the services required by this Agreement at the Company’s
principal offices located in Silver Spring, Maryland or such other location mutually agreed upon by the Company and the Executive
(the “Principal Location”), except for travel to other locations as may be necessary to fulfill the Executive’s
duties and responsibilities hereunder.

 

(b)          Compensation,
Benefits, Etc.

 

(i)             Base
Salary. During the Employment Period, the Executive shall receive a base salary (the “Base Salary”)
of $380,600 per annum. The Base Salary shall be reviewed annually by the Compensation Committee (the “Compensation
Committee”) of the Board of Directors of the Company (the “Board”) and may be increased
from time to time by the Compensation Committee in its sole discretion. The Base Salary shall be paid in accordance with the Company’s
normal payroll practices for executive salaries generally, but no less often than monthly. The Base Salary may be increased in
the Compensation Committee’s discretion, but not reduced, and the term “Base Salary” as utilized in this Agreement
shall refer to the Base Salary as so increased.

 

(ii)            Annual
Cash Bonus. In addition to the Base Salary, the Executive shall be eligible to earn, for each fiscal year of the Company ending
during the Employment Period, a discretionary cash performance bonus (an “Annual Bonus”) under the Company’s
bonus plan or program applicable to senior executives. The Executive’s target Annual Bonus shall be set at 45% of the Base
Salary actually paid for such year (the “Target Bonus”). The actual amount of any Annual Bonus shall
be determined by reference to the attainment of Company performance metrics and/or individual performance objectives, in each case,
as determined by the Compensation Committee, and may be greater or less than the Target Bonus (or zero). Subject to Section 4(a)(i) hereof,
payment of any Annual Bonus(es), to the extent any Annual Bonus(es) become payable, will be contingent upon the Executive’s
continued employment through the applicable payment date. The Company will pay any such bonus that has been duly earned and awarded
by the Board as soon as administratively possible following its approval by the Board and, in any event, no later than the later
of (i) the fifteenth day of the third month after the end of the Company’s fiscal year in which such bonus is earned
or (ii) March 15 following the calendar year in which such bonus is earned.

 

    2

     

    

 

(iii)            Benefits.
During the Employment Period, the Executive (and the Executive’s spouse and/or eligible dependents to the extent provided
in the applicable plans and programs) shall be eligible to participate in and be covered under the health and welfare benefit plans
and programs maintained by the Company for the benefit of its employees from time to time, pursuant to the terms of such plans
and programs including any medical and dental insurance plans and programs. During the Employment Period, the Company shall provide
the Executive and the Executive’s eligible dependents with coverage under its group health plans. In addition, during the
Employment Period, Executive shall be eligible to participate in any retirement, savings and other employee benefit plans and programs
maintained from time to time by the Company for the benefit of its senior executive officers. Nothing contained in this Section 2(b)(iii) shall
create or be deemed to create any obligation on the part of the Company to adopt or maintain any health, welfare, retirement or
other benefit plan or program at any time or to create any limitation on the Company’s ability to modify or terminate any
such plan or program.

 

(iv)           Expenses.
During the Employment Period, the Executive shall be entitled to receive prompt reimbursement for all reasonable business expenses
incurred by the Executive in accordance with the policies, practices and procedures of the Company provided to employees of the
Company.

 

(v)            Fringe
Benefits. During the Employment Period, the Executive shall be eligible to receive such fringe benefits and perquisites as
are provided by the Company to its employees from time to time, in accordance with the policies, practices and procedures of the
Company, and shall receive such additional fringe benefits and perquisites as the Company may, in its discretion, from time-to-time
provide.

 

(vi)           Vacation.
During the Employment Period, the Executive shall be entitled to paid vacation in accordance with the plans, policies, programs
and practices of the Company applicable to its senior executives in effect from time to time, but in no event shall the Executive
be entitled to less than four (4) weeks of vacation per calendar year (pro-rated for any partial year of service).

 

3.            Termination
of Employment.

 

(a)           Death
or Disability. The Executive’s employment shall terminate automatically upon the Executive’s death during the Employment
Period. Either the Company or the Executive may terminate the Executive’s employment in the event of the Executive’s
Disability during the Employment Period. For purposes of this Agreement, “Disability” shall mean any
disability or incapacity that (i) renders Executive unable to substantially perform his duties hereunder for ninety (90) days
during any 12-month period or (ii) would reasonably be expected to render Executive unable to substantially perform his duties
for ninety (90) days during any 12-month period, in each case as determined by the Board in its good faith judgment.

 

(b)           Termination
by the Company. The Company may terminate the Executive’s employment during the Employment Period for Cause or without
Cause. For purposes of this Agreement, “Cause” shall mean the occurrence of any one or more of the following
events unless, to the extent capable of correction, the Executive fully corrects the circumstances constituting Cause within fifteen
(15) days after receipt of the Notice of Termination (as defined below):

 

(i)             Executive
performing his duties, in the good faith opinion of the Board, in a grossly negligent or reckless manner or with willful malfeasance;

 

(ii)            Executive
exhibiting habitual drunkenness or engaging in substance abuse;

 

    3

     

    

 

(iii)           Executive
committing any material violation of any state or federal law relating to the workplace environment (including, without limitation,
laws relating to sexual harassment or age, sex or other prohibited discrimination) or any material violation of any Company policy;

 

(iv)           Executive
willfully failing or refusing to perform in the usual manner at the usual time those duties which he regularly and routinely performs
in connection with the business of the Company or such other duties reasonably related to the capacity in which he is employed
hereunder which may be assigned to him by the Board;

 

(v)            Executive
performing any material action when specifically and reasonably instructed not to do so by the Chairman or the Board;

 

(vi)           Executive
breaching Sections 7, 8 and 9 hereof;

 

(vii)          Executive
committing any fraud or using or appropriating for his or her personal use or benefit any funds, properties or opportunities of
the Company not authorized by the Board to be so used or appropriated; or

 

(viii)         Executive
being convicted of any felony or any other crime related to his employment or involving moral turpitude.

 

The Company shall not be entitled to terminate
Executive for Cause pursuant to clause (iii), (iv), (v) or (vi) unless the Company provides written notice stating in
reasonable detail the basis for termination and a fifteen (15) day opportunity to cure to Executive (unless (1) the Company
reasonably determines that providing such opportunity to cure to Executive is reasonably likely to have a material adverse effect
on its business, financial condition, results of operations, prospects or assets, (2) the facts and circumstances underlying
such termination are not able to be cured or (3) the Company has previously provided Executive an opportunity to cure the
applicable issue; in the case of (1), (2) or (3), the Company may terminate Executive without providing an opportunity to
cure).

 

(c)           Termination
by the Executive. The Executive’s employment may be terminated by the Executive for any reason, including with Good Reason
or by the Executive without Good Reason. For purposes of this Agreement, “Good Reason” shall mean the
occurrence of any one or more of the following events without the Executive’s prior written consent, unless the Company fully
corrects the circumstances constituting Good Reason (provided such circumstances are capable of correction) as provided below:

 

(i)             A
material reduction in the Executive’s job responsibilities and duties for the Company;

 

(ii)            A
material reduction in the Executive’s Base Salary; or

 

(iii)           a
requirement imposed by the Company on the Executive that Executive’s principal place of employment be anywhere other than
within a 50 mile radius of the Executive’s Principal Location, except for required travel on Company business to an extent
substantially consistent with Executive's business travel obligations, that, in any such case, is not cured by the Company within
fifteen (15) days after the Company’s receipt of written notice from the Executive of such event.

 

    4

     

    

 

Notwithstanding the foregoing, the Executive
will not be deemed to have resigned for Good Reason unless (1) the Executive provides the Company with written notice setting
forth in reasonable detail the facts and circumstances claimed by the Executive to constitute Good Reason within sixty (60) days
after the date of the occurrence of any event that the Executive knows or should reasonably have known to constitute Good Reason,
(2) the Company fails to cure such acts or omissions within thirty (30) days following its receipt of such notice, and (3) the
effective date of the Executive’s termination for Good Reason occurs no later than sixty (60) days after the expiration of
the Company’s cure period.

 

(d)          Notice
of Termination. Any termination by the Company for Cause, or by the Executive for Good Reason, shall be communicated by a Notice
of Termination to the other parties hereto given in accordance with Section 13(d) hereof. For purposes of this Agreement,
a “Notice of Termination” means a written notice which (i) indicates the specific termination provision
in this Agreement relied upon, (ii) sets forth in reasonable detail the facts and circumstances claimed to provide a basis
for termination of the Executive’s employment under the provision so indicated and (iii) if the Date of Termination
(as defined below) is other than the date of receipt of such notice, specifies the termination date (which date shall be not more
than thirty (30) days after the giving of such notice). The failure by the Executive or the Company to set forth in the Notice
of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of the
Executive or the Company, respectively, hereunder or preclude the Executive or the Company, respectively, from asserting such fact
or circumstance in enforcing the Executive’s or the Company’s rights hereunder.

 

(e)          Termination
of Offices and Directorships; Return of Property. Upon termination of the Executive’s employment for any reason, unless
otherwise specified in a written agreement between the Executive and the Company, the Executive shall be deemed to have resigned
from all offices, directorships, and other employment positions if any, then held with the Company, and shall take all actions
reasonably requested by the Company to effectuate the foregoing. In addition, upon the termination of the Executive’s employment
for any reason, the Executive agrees to return to the Company all documents of the Company and its affiliates (and all copies thereof)
and all other Company or Company affiliate property that the Executive has in his or her possession, custody or control. Such property
includes, without limitation: (i) any materials of any kind that the Executive knows contain or embody any proprietary or
confidential information of the Company or an affiliate of the Company (and all reproductions thereof), (ii) computers (including,
but not limited to, laptop computers, desktop computers and similar devices) and other portable electronic devices (including,
but not limited to, tablet computers), cellular phones/smartphones, credit cards, phone cards, entry cards, identification badges
and keys, and (iii) any correspondence, drawings, manuals, letters, notes, notebooks, reports, programs, plans, proposals,
financial documents, or any other documents concerning the customers, business plans, marketing strategies, products and/or processes
of the Company or any of its affiliates and any information received from the Company or any of its affiliates regarding third
parties.

 

4.            Obligations
of the Company upon Termination. Upon a termination of the Executive’s employment for any reason, the Executive shall
be paid, in a single lump-sum payment on the date of the Executive’s termination of employment, the aggregate amount of the
Executive’s earned but unpaid Base Salary and accrued but unpaid vacation pay through the date of such termination (the “Accrued
Obligations”).

 

(a)          Without
Cause or For Good Reason. If the Executive’s employment with the Company is terminated during the Employment Period (x) by
the Company without Cause (other than by reason of the Executive’s death or Disability or due to the expiration of the Employment
Period) or (y) by the Executive for Good Reason (in either case, a “Qualifying Termination”), then
following the Executive’s Separation from Service (as defined below) (such date, the “Date of Termination”),
in each case, subject to and conditioned upon compliance with Section 4(d) hereof, in addition to the Accrued Obligations:

 

    5

     

    

 

(i)            Cash
Severance. The Company shall continue to pay to the Executive the Executive’s Base Salary in effect on the Date of Termination
during the period beginning on the Date of Termination and ending on the 12-month anniversary of the Date of Termination (the “Severance
Period”) in installments in accordance with the Company’s regular payroll practices as of the Date of Termination;

 

(ii)           COBRA.
During the Severance Period, subject to the Executive’s valid election to continue healthcare coverage under Section 4980B
of the Internal Revenue Code and the regulations thereunder (together, the “Code”), the Company shall
continue to provide the Executive and the Executive’s eligible dependents with coverage under its group health plans at the
same levels and the same cost to the Executive as would have applied if the Executive’s employment had not been terminated
based on the Executive’s elections in effect on the Date of Termination (the “COBRA Payments”),
provided, however, that (A) if any plan pursuant to which such benefits are provided is not, or ceases
prior to the expiration of the period of continuation coverage to be, exempt from the application of Section 409A (as defined
below) under Treasury Regulation Section 1.409A-1(a)(5), or (B) the Company is otherwise unable to continue to cover
the Executive under its group health plans without incurring penalties (including without limitation, pursuant to Section 2716
of the Public Health Service Act or the Patient Protection and Affordable Care Act), then, in either case, an amount equal to each
remaining Company subsidy shall thereafter be paid to the Executive in substantially equal monthly installments over the continuation
coverage period (or the remaining portion thereof).

 

(iii)           Change
in Control. Notwithstanding the foregoing, if the Qualifying Termination occurs within the 12-month period following
a Change in Control, as defined in the Company’s 2020 Incentive Award Plan, as amended (and such Change in Control constitutes
a “change in control event” as defined in Treasury Regulations Section 1.409A-3(i)(5)), then in lieu of the foregoing
payments set forth in Section 4(a)(i), the Company shall pay to the Executive the sum of (x) 12-months of Executive’s
Base Salary in effect on the Date of Termination and (y) 1.0 times the Executive’s Target Bonus for the year in which
the Date of Termination occurs, during the Severance Period in installments in accordance with the Company’s regular payroll
practices as of the Date of Termination. In addition, unless otherwise explicitly set forth in any award agreement, any unvested
equity awards outstanding immediately prior to the Date of Termination shall automatically become fully vested and exercisable
(as applicable).

 

Notwithstanding the foregoing, it shall
be a condition to the Executive’s right to receive the amounts provided for in Sections 4(a)(i), 4(a)(ii) and 4(a)(iii) hereof
that the Executive execute and deliver to the Company an effective release of claims in substantially the form attached hereto
as Exhibit B (the “Release”) within twenty-one (21) days (or, to the extent required by law,
forty-five (45) days) following the Date of Termination and that the Executive not revoke such Release during any applicable revocation
period.

 

(b)          For
Cause, Without Good Reason or Other Terminations. If the Company terminates the Executive’s employment for Cause, the
Executive terminates the Executive’s employment without Good Reason, or the Executive’s employment terminates for any
other reason not enumerated in Sections 4(a) or 4(b) hereof, in any case, during the Employment Period, or if the Executive’s
employment with the Company is terminated due to the expiration of the Employment Period, then, in any case, the Company shall
pay to the Executive the Accrued Obligations in cash within thirty (30) days after the Date of Termination (or by such earlier
date as may be required by applicable law), and the Executive shall have no further rights hereunder.

 

    6

     

    

 

(c)          Six-Month
Delay. Notwithstanding anything to the contrary in this Agreement, no compensation or benefits, including without limitation
any severance payments or benefits payable under Section 4 hereof, shall be paid to the Executive during the six (6)-month
period following the Executive’s “separation from service” from the Company (within the meaning of Section 409A,
a “Separation from Service”) if the Company determines that paying such amounts at the time or times
indicated in this Agreement would be a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code. If the payment
of any such amounts is delayed as a result of the previous sentence, then on the first day of the seventh month following the date
of Separation from Service (or such earlier date upon which such amount can be paid under Section 409A without resulting in
a prohibited distribution, including as a result of the Executive’s death), the Company shall pay the Executive a lump-sum
amount equal to the cumulative amount that would have otherwise been payable to the Executive during such period.

 

(d)          Exclusive
Benefits. Except as expressly provided in this Section 4 and subject to Section 5 hereof, the Executive shall not
be entitled to any additional payments or benefits upon or in connection with the Executive’s termination of employment.

 

5.            Non-Exclusivity
of Rights. Amounts which are vested benefits or which the Executive is otherwise entitled to receive under any plan, policy,
practice or program of or any contract or agreement with the Company at or subsequent to the Date of Termination shall be payable
in accordance with such plan, policy, practice or program or contract or agreement except as explicitly modified by this Agreement.

 

6.            Excess
Parachute Payments, Limitation on Payments.

 

(a)           Best
Pay Cap. Notwithstanding any other provision of this Agreement, in the event that any payment or benefit received or to be
received by the Executive (including any payment or benefit received in connection with a termination of the Executive’s
employment, whether pursuant to the terms of this Agreement or any other plan, arrangement or agreement) (all such payments and
benefits, including the payments and benefits under Section 4 hereof, being hereinafter referred to as the “Total
Payments”) would be subject (in whole or part), to the excise tax imposed under Section 4999 of the Code (the
 “Excise Tax”), then, after taking into account any reduction in the Total Payments provided by reason
of Section 280G of the Code in such other plan, arrangement or agreement, the cash severance payments under this Agreement
shall first be reduced, and the noncash severance payments hereunder shall thereafter be reduced, to the extent necessary so that
no portion of the Total Payments is subject to the Excise Tax but only if (i) the net amount of such Total Payments, as so
reduced (and after subtracting the net amount of federal, state and local income taxes on such reduced Total Payments and after
taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is
greater than or equal to (ii) the net amount of such Total Payments without such reduction (but after subtracting the net
amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which the Executive would
be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal
exemptions attributable to such unreduced Total Payments).

 

    7

     

    

 

(b)          Certain
Exclusions. For purposes of determining whether and the extent to which the Total Payments will be subject to the Excise Tax,
(i) no portion of the Total Payments the receipt or enjoyment of which the Executive shall have waived at such time and in
such manner as not to constitute a “payment” within the meaning of Section 280G(b) of the Code shall be taken
into account; (ii) no portion of the Total Payments shall be taken into account which, in the written opinion of an independent,
nationally recognized accounting or consulting firm (the “Independent Advisors”) selected by the Company,
does not constitute a “parachute payment” within the meaning of Section 280G(b)(2) of the Code (including
by reason of Section 280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, no portion of such Total Payments
shall be taken into account which, in the opinion of the Independent Advisors, constitutes reasonable compensation for services
actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the “base amount”
(as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation; and (iii) the value of
any non-cash benefit or any deferred payment or benefit included in the Total Payments shall be determined by the Independent Advisors
in accordance with the principles of Sections 280G(d)(3) and (4) of the Code.

 

7.            Nondisclosure
and Nonuse of Confidential Information.

 

(a)          The
Executive’s employment creates a relationship of confidence and trust between the Company and the Executive with respect
to any information that is applicable to the business of the Company or the affiliates, any information that is otherwise used,
developed or obtained by the Company or any affiliate in connection with its business and any information that is applicable to
the business of any client, customer or other commercial partner of the Company or the affiliates, which may be made known to the
Executive or learned by the Executive in such context during the period of his employment with the Company. All such information,
whether oral or written, has commercial value in the business in which the Company is engaged and is referred to herein as “Confidential
Information”.

 

(b)          The
Company owns all right, title and interest in and to all Confidential Information. The Executive hereby assigns to the Company
all right, title and interest that he may have acquired or hereafter may acquire in all Confidential Information. The Executive
shall, at all times, both during the Employment Period and after the termination of the Employment Period, keep in confidence and
trust all Confidential Information and the Executive shall not use or disclose any Confidential Information except as may be necessary
in the ordinary course of performing his duties as an employee of the Company. Upon termination of the Employment Period, or at
any time upon the request of the Company before such termination, the Executive shall promptly (but no later than five (5) days
after the earlier of such termination or such request) destroy or deliver to the Company, at the Company’s option, all Confidential
Information in the Executive’s control or possession and a written certification of the Executive’s compliance with
such obligations.

 

(c)          the
Executive hereby represents and warrants to the Company that neither his performance of the terms of this Agreement nor his employment
with the Company will breach or conflict with any agreement, understanding, policy or other arrangement that he is a party to or
otherwise subject to or bound by (including, without limitation, any such agreement, understanding, policy or arrangement (i) relating
to nondisclosure or nonuse of proprietary information, knowledge or data or (ii) that otherwise assigns, licenses or otherwise
transfers any interest in or to any Company Innovation (as defined below) to person or entity other than the Company). The Executive
shall not disclose to the Company or otherwise use any confidential or proprietary information or material belonging to any other
person or entity.

 

(d)          Notice
of Immunity Under the Economic Espionage Act of 1996, as amended by the Defend Trade Secrets Act of 2016 (“DTSA”).
Notwithstanding any other provision of this Agreement:

 

(e)          the
Executive will not be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade
secret that: (A) is made: (1) in confidence to a federal, state, or local government official, either directly or indirectly,
or to an attorney; and (2) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is
made in a complaint or other document that is filed under seal in a lawsuit or other proceeding.

 

    8

     

    

 

(f)           If
the Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, the Executive may disclose
the Company’s trade secrets to the Executive’s attorney and use the trade secret information in the court proceeding
if the Executive: (A) files any document containing the trade secret under seal; and (B) does not disclose the trade
secret, except pursuant to court order.

 

(g)          the
Executive shall (i) comply with all Company security policies and procedures as in force from time to time including, without
limitation, those regarding computer equipment, telephone systems, voicemail systems, facilities access, monitoring, key cards,
access codes, Company intranet, internet, social media and instant messaging systems, e-mail systems, document storage systems,
software licenses, data security, encryption, firewalls and passwords (the “Facilities and Information Technology Resources”);
(ii) not access or use any Facilities and Information Technology Resources except as authorized by the Company; and (iii) not
access or use any Facilities and Information Technology Resources in any manner after the termination of the Executive’s employment by
the Company, whether termination is voluntary or involuntary.

 

8.            Inventions
and Proprietary Rights.

 

(a)          the
Executive represents and warrants to the Company that he does not have any right, title or interest in or to any Innovation (as
defined below) applicable to the business of the Company or relating in any way to the Company’s business or demonstrably
anticipated research and development or business that were conceived, reduced to practice, created, derived, developed or made
by the Executive prior to the date hereof.

 

(b)          the
Executive hereby agrees promptly to disclose and describe to the Company, and the Executive hereby assigns to the Company all right,
title and interest in and to, each of the Innovations and all associated intellectual property rights that the Executive may solely
or jointly conceive, reduce to practice, create, derive, develop or make during the period of his employment with the Company that
(i) relate to the Company’s or any affiliate’s business or actual or demonstrably anticipated research or development,
(ii) were developed on any amount of the Company’s or any affiliate’s time or with the use of any of the Company’s
or any affiliate’s materials, equipment, supplies, facilities or information or (iii) resulted from any work that the
Executive performed for the Company or any affiliate (collectively, the “Company Innovations”). the Executive
further acknowledges and agrees that all Company Innovations, including, without limitation, any computer programs, programming
documentation, and other works of authorship, are “works made for hire” for purposes of the Company’s rights
under copyright laws and the Executive hereby assigns to the Company any and all right, title and interest that the Executive may
have acquired or may hereafter acquire in such Company Innovations. Any assignment of copyright hereunder includes all rights of
paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred to as “moral rights”
(collectively “Moral Rights”). To the extent that such Moral Rights cannot be assigned under applicable
law and to the extent the following is allowed by the laws in the various countries where Moral Rights exist, the Executive hereby
waives such Moral Rights and consents to any action of the Company and the affiliates that would violate such Moral Rights in the
absence of such consent. The Executive shall confirm any such waivers and consents from time to time as requested by the Company.
To the extent that any right, title or interest in or to any Company Innovation cannot be assigned by the Executive to the Company,
the Executive hereby grants to the Company an exclusive, royalty-free, transferable, irrevocable, worldwide license (with rights
to sublicense through multiple tiers of sublicensees) to practice such non-assignable right, title or interest. To the extent that
any right, title or interest in or to any Company Innovation can be neither assigned nor licensed by the Executive to the Company,
the Executive hereby irrevocably waives and agrees never to assert such non-assignable and non-licensable right, title or interest
against the Company, any affiliate or any of their successors in interest to such non-assignable and non-licensable rights.

 

    9

     

    

 

(c)            the
Executive recognizes that Innovations and Confidential Information relating to his activities while working for the Company and
conceived, reduced to practice, created, derived, developed or made by the Executive, alone or with others, within six (6) months
after termination of his employment with the Company may have been conceived, reduced to practice, created, derived, developed
or made, as applicable, in significant part while employed by the Company. Accordingly, the Executive agrees that such Innovations
and Confidential Information shall be presumed to have been conceived, reduced to practice, created, derived, developed or made,
as applicable, during his employment with the Company and shall be assigned to the Company unless and until the Executive has established
the contrary by written evidence satisfying the clear and convincing standard of proof.

 

(d)            the
Executive shall perform, during and after his employment with the Company, all acts deemed necessary or desirable by the Company
to permit and assist the Company, at the Company’s expense, in obtaining and enforcing the full benefits, enjoyment, rights
and title throughout the world in the Confidential Information and Innovations assigned or licensed to, or whose rights are irrevocably
waived and shall not be asserted against, the Company and the affiliates under this Agreement. Such acts may include, but are not
limited to, execution of documents and assistance or cooperation (i) in the filing, prosecution, registration, and memorialization
of assignment of any applicable patents, copyrights, mask works or other applications, (ii) in the enforcement of any applicable
patents, copyrights, mask works, Moral Rights, trade secrets or other rights, and (iii) in other legal proceedings related
to the Confidential Information or Innovations.

 

(e)            In
the event that the Company is unable for any reason to secure the Executive’s signature to any document required to file,
prosecute, register, or memorialize the assignment of any patent, copyright, mask work or other applications or to enforce any
patent, copyright, mask work, Moral Right, trade secret or other right under any Confidential Information (including improvements
thereof) or any Innovations (including derivative works, improvements, renewals, extensions, continuations, divisionals, continuations
in part, continuing patent applications, reissues, and reexaminations thereof), the Executive hereby irrevocably designates and
appoints the Company and the Company’s duly authorized officers and agents as his agents and attorneys-in-fact to act for
and on his behalf and instead of the Executive (i) to execute, file, prosecute, register and memorialize the assignment of
any such application, (ii) to execute and file any documentation required for such enforcement and (iii) to do all other
lawfully permitted acts to further the filing, prosecution, registration, memorialization of assignment, issuance, and enforcement
of patents, copyrights, mask works, Moral Rights, trade secrets or other rights under the Confidential Information or Innovations,
all with the same legal force and effect as if executed by the Executive.

 

(f)            The
term “Innovations” means all processes, improvements, inventions (whether or not protectable under patent
laws), works of authorship, information fixed in any tangible medium of expression (whether or not protectable under copyright
laws), moral rights, mask works, trademarks, trade names, trade dress, trade secrets, know-how, ideas (whether or not protectable
under trade secret laws) and all other subject matter protectable under patent, copyright, moral right, mask work, trademark, trade
secret or other laws and includes, without limitation, all new or useful art, combinations, designs, developments, modifications,
derivative works, discoveries, formulae, techniques and all goodwill associated with any of the foregoing.

 

(g)           The
Executive hereby irrevocably consents to any and all uses and displays, by the Company and its affiliates, agents, representatives
and licensees, of the Executive’s name, voice, likeness, image, appearance, and biographical information in, on or in connection
with any pictures, photographs, audio and video recordings, digital images, websites, television programs and advertising, other
advertising and publicity, sales and marketing brochures, books, magazines, other publications, CDs, DVDs, tapes, and all other
printed and electronic forms and media throughout the world, at any time during or after the period of his employment by the Company,
for all legitimate commercial and business purposes of the Company (“Permitted Uses”) without further
consent from or royalty, payment, or other compensation to the Executive. the Executive hereby forever waives and releases the
Company and its directors, managing members, officers, employees and agents from any and all claims, actions, damages, losses,
costs, expenses, and liability of any kind, arising under any legal or equitable theory whatsoever at any time during or after
the period of his employment by the Company, arising directly or indirectly from the Company’s and its affiliates’,
agents’, representatives’ and licensees’ exercise of their rights in connection with any Permitted Uses.

 

    10

     

    

 

9.             Non-Compete;
Non-Solicitation.

 

(a)           The
Executive acknowledges that, in the course of his employment with the Company and/or the Restricted Affiliates (as defined below),
he has become familiar, or will become familiar, with trade secrets and with other confidential information concerning the Company
and the Restricted Affiliates and that his services have been and will be of special, unique and extraordinary value to the Company
and the Restricted Affiliates. the Executive understands that the following restrictions may limit his ability to earn a livelihood
in a business similar to the business of the Company or any of the Restricted Affiliates, but he nevertheless believes that he
will receive sufficient consideration and other benefits as an equityholder and an employee of the Company and as otherwise provided
hereunder to clearly justify such restrictions which, in any event (given his education, skills and ability), the Executive does
not believe would prevent him from otherwise earning a living. The Executive further understands that the provisions of Sections
7 through 9, inclusive, are reasonable and necessary to preserve the business of the Company and the Restricted Affiliates. “Restricted
Affiliate” means any affiliate for which, during the twenty-four (24) month period preceding the Termination Date,
the Executive served as an officer or director or the Executive provided any material services.

 

(b)           In
light of Section 9(a), the Executive agrees that while the Executive is employed by the Company and for twelve (12) months
thereafter (such period, subject to automatic extension for an additional period equal to the period of any breach of the covenants
in this Section 9, shall be referred to herein as the “Non-Compete Period”), he shall not directly
or indirectly own, manage, operate, control, finance or invest in, participate in, consult with, render services for, act as an
officer, director, manager, partner, principal, agent, representative, contractor or advisor of or to, or in any manner engage
in or be associated with, hold any interest in, be employed by or represent any other business competing with the businesses or
the services or products of the Company or the Restricted Affiliates as such businesses and/or services or products exist or are
in the process of being formed, developed or acquired as of the Termination Date. Nothing herein shall prohibit the Executive from
being a passive owner of not more than one percent (1%) of the outstanding stock of any class of a corporation which is publicly
traded, so long as the Executive has no active participation in the business of such corporation.

 

(c)           Furthermore,
in light of Section 9(a), the Executive agrees that:

 

(i)             during
the Non-Compete Period, the Executive shall not directly or indirectly through another person or entity: (x) induce or attempt
to induce any employee or independent contractor of the Company or any Restricted Affiliate to leave the employ of or engagement
with the Company or such Restricted Affiliate, or in any way interfere with the relationship between the Company or any such Restricted
Affiliate, on the one hand, and any employee or independent contractor thereof, on the other hand; or (y) hire or engage any
person who was an employee or independent contractor of the Company until twelve months after such individual’s relationship
with the Company or any Restricted Affiliate has been terminated; and

 

    11

     

    

 

(ii)            during
the Non-Compete Period, the Executive shall not directly or indirectly through another person or entity: (x) induce or attempt
to induce any customer (it being understood that the term “customer” as used throughout this Agreement includes any
person or entity that is receiving services from the Company or any Restricted Affiliate or that is directly or indirectly providing
or referring business for the Company or any Restricted Affiliate), supplier, independent contractor, licensee or other business
relation of the Company or any Restricted Affiliate to cease doing business with the Company or any Restricted Affiliate, or in
any way interfere with the relationship between any such customer, supplier, independent contractor, licensee or business relation,
on the one hand, and the Company or any Restricted Affiliate, on the other hand; or (y) solicit any customer of the Company
or any Restricted Affiliate in order to offer products or services similar to those offered by the Company or any Restricted Affiliate.

 

(d)           The
Executive shall inform any prospective or future employer of any and all restrictions contained in this Agreement and provide such
employer with a copy of such restrictions (but no other terms of this Agreement) prior to the commencement of that employment.

 

(e)            If,
at the time of enforcement of Section 9, a court holds that the restrictions stated herein are unreasonable under the circumstances
then existing, the Executive and the Company agree that the maximum period, scope or geographical area reasonable under such circumstances
shall be substituted for the stated period, scope or area so as to protect the Company to the greatest extent possible under applicable
law from improper competition.

 

(f)            In
the event of any breach or violation by the Executive of any of the restrictions contained in Section 9, any time period specified
herein shall abate during the time of any such breach or violation thereof and that portion remaining at the time of commencement
of any such breach or violation shall not begin to run until such breach or violation has been cured in all respects.

 

10.           Enforcement.
Because the Executive’s services are unique and because the Executive has access to Confidential Information and Company
Innovations, the parties hereto agree that monetary damages alone would be an inadequate remedy for any breach of this Agreement.
Therefore, in the event of a breach or threatened breach of this Agreement, the Company or its successors or assigns may, in addition
to other rights and remedies existing in their favor at law or in equity, apply to any court of competent jurisdiction for specific
performance and/or injunctive or other relief in order to enforce, or prevent any violations of, the provisions hereof (without
posting a bond or other security) or require the Executive to account for and pay over to the Company all compensation, profits,
moneys, accruals, increments or other benefits derived from or received as a result of any transactions constituting a breach of
the covenants contained in this Agreement, if and when final judgment of a count of competent jurisdiction is so entered against
the Executive. The rights and remedies of the Company under this Agreement are not exclusive of or limited by any other rights
or remedies which they may have, whether at law, in equity, by contract or otherwise, all of which shall be cumulative (and not
alternative). Without limiting the generality of the foregoing, the rights and remedies of the Company under this Agreement, and
the obligations and liabilities of the Executive under this Agreement, are in addition to their respective rights, remedies, obligations
and liabilities under the laws of unfair competition, laws relating to misappropriation of trade secrets and all other laws, rules and
regulations. No failure on the part of any person or entity to exercise any power, right, privilege or remedy under this Agreement,
and no delay on the part of any person or entity in exercising any power, right, privilege or remedy under this Agreement, shall
operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege
or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. No person or
entity shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this
Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly
executed and delivered on behalf of such person or entity; and any such waiver shall not be applicable or have any effect except
in the specific instance in which it is given.

 

    12

     

    

 

11.           Representations.
The Executive hereby represents and warrants to the Company that (a) the Executive is entering into this Agreement voluntarily
and that the performance of the Executive’s obligations hereunder will not violate any agreement between the Executive and
any other person, firm, organization or other entity, and (b) the Executive is not bound by the terms of any agreement with
any previous employer or other party to refrain from competing, directly or indirectly, with the business of such previous employer
or other party that would be violated by the Executive’s entering into this Agreement and/or providing services to the Company
pursuant to the terms of this Agreement.

 

12.           Successors.

 

(a)            This
Agreement is personal to the Executive and, without the prior written consent of the Company, shall not be assignable by the Executive
otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable
by the Executive’s legal representatives.

 

(b)            This
Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

 

(c)            The
Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially
all of the business and/or assets of the Company to assume and agree to perform this Agreement in the same manner and to the same
extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, “Company”
shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees
to perform this Agreement by operation of law, or otherwise.

 

13.           Miscellaneous.

 

(a)           Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Maryland, without reference
to principles of conflict of laws. The captions of this Agreement are not part of the provisions hereof and shall have no force
or effect.

 

(b)            Compensation
Recovery Policy. Executive acknowledges and agrees that, to the extent the Company adopts any claw-back or similar policy pursuant
to the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, and any rules and regulations promulgated thereunder,
he or she shall take all action necessary or appropriate to comply with such policy (including, without limitation, entering into
any further agreements, amendments or policies necessary or appropriate to implement and/or enforce such policy with respect to
past, present and future compensation, as appropriate).

 

(c)           Whistleblower
Protections and Trade Secrets. Notwithstanding anything to the contrary contained herein, nothing in this Agreement prohibits
Executive from reporting possible violations of federal law or regulation to any United States governmental agency or entity in
accordance with the provisions of and rules  promulgated under Section 21F of the Securities
Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of
state or federal law or regulation (including the right to receive an award for information provided to any such government agencies).
Furthermore, in accordance with 18 U.S.C. § 1833, notwithstanding anything to the contrary in this Agreement: (i) Executive
shall not be in breach of this Agreement, and shall not be held criminally or civilly liable under any federal or state trade secret
law (A) for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official
or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (B) for the disclosure
of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made
under seal; and (ii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law,
Executive may disclose the trade secret to Executive’s attorney, and may use the trade secret information in the court proceeding,
if Executive files any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant
to court order.

 

    13

     

    

 

(d)            Notices.
All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party or by
registered or certified mail, return receipt requested, postage prepaid, addressed as follows:

 

If
to the Executive: at the Executive’s most recent address on the records of the Company.

 

If
to the Company:

 

Azyio Biologics, Inc.

12510 Prosperity Drive

Suite 1-370

Silver Spring, MD 20904

Attention: Board of Directors

 

with a copy to:

 

Latham & Watkins LLP

885 Third Avenue

New York, NY 10022-4802

Attn: [XXX]

 

or to such other address as either party
shall have furnished to the other in writing in accordance herewith. Notice and communications shall be effective when actually
received by the addressee.

 

(e)            Sarbanes-Oxley
Act of 2002. Notwithstanding anything herein to the contrary, if the Company determines, in its good faith judgment, that any
transfer or deemed transfer of funds hereunder is likely to be construed as a personal loan prohibited by Section 13(k) of
the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange
Act”), then such transfer or deemed transfer shall not be made to the extent necessary or appropriate so as not to
violate the Exchange Act and the rules and regulations promulgated thereunder.

 

(f)            Section 409A
of the Code.

 

(i)            To
the extent applicable, this Agreement shall be interpreted in accordance with Section 409A of the Code and Department of Treasury
regulations and other interpretive guidance issued thereunder (together, “Section 409A”). Notwithstanding
any provision of this Agreement to the contrary, if the Company determines that any compensation or benefits payable under this
Agreement may be subject to Section 409A, the Company shall work in good faith with the Executive to adopt such amendments
to this Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect),
or take any other actions, that the Company determines are necessary or appropriate to avoid the imposition of taxes under Section 409A,
including without limitation, actions intended to (i) exempt the compensation and benefits payable under this Agreement from
Section 409A, and/or (ii) comply with the requirements of Section 409A; provided, however,
that this Section 10(d) shall not create an obligation on the part of the Company to adopt any such amendment, policy
or procedure or take any such other action, nor shall the Company have any liability for failing to do so.

 

    14

     

    

 

(ii)            Any
right to a series of installment payments pursuant to this Agreement is to be treated as a right to a series of separate payments.
To the extent permitted under Section 409A, any separate payment or benefit under this Agreement or otherwise shall not be
deemed “nonqualified deferred compensation” subject to Section 409A to the extent provided in the exceptions in
Treasury Regulation Section 1.409A-1(b)(4), Section 1.409A-1(b)(9) or any other applicable exception or provision
of Section 409A. Any payments subject to Section 409A that are subject to execution of a waiver and release which may
be executed and/or revoked in a calendar year following the calendar year in which the payment event (such as termination of employment)
occurs shall commence payment only in the calendar year in which the consideration period or, if applicable, release revocation
period ends, as necessary to comply with Section 409A. All payments of nonqualified deferred compensation subject to Section 409A
to be made upon a termination of employment under this Agreement may only be made upon Employee’s “separation from
service” from the Company (within the meaning of Section 409A, a “Separation from Service”).

 

(iii)           To
the extent that any payments or reimbursements provided to the Executive under this Agreement are deemed to constitute compensation
to the Executive to which Treasury Regulation Section 1.409A-3(i)(1)(iv) would apply, such amounts shall be paid or reimbursed
reasonably promptly, but not later than December 31 of the year following the year in which the expense was incurred. The
amount of any such payments eligible for reimbursement in one year shall not affect the payments or expenses that are eligible
for payment or reimbursement in any other taxable year, and the Executive’s right to such payments or reimbursement of any
such expenses shall not be subject to liquidation or exchange for any other benefit.

 

(g)            Severability.
The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other
provision of this Agreement.

 

(h)            Withholding.
The Company may withhold from any amounts payable under this Agreement such federal, state, local or foreign taxes as shall be
required to be withheld pursuant to any applicable law or regulation.

 

(i)             No
Waiver. The Executive’s or the Company’s failure to insist upon strict compliance with any provision of this Agreement
or the failure to assert any right the Executive or the Company may have hereunder, including, without limitation, the right of
the Executive to terminate employment for Good Reason pursuant to Section 3(c) hereof, shall not be deemed to be a waiver
of such provision or right or any other provision or right of this Agreement.

 

(j)             Entire
Agreement. As of the Effective Date, this Agreement constitutes the final, complete and exclusive agreement between the Executive
and the Company with respect to the subject matter hereof and replaces and supersedes any and all other agreements, offers or promises,
whether oral or written, by any member of the Company and its subsidiaries or affiliates, or representative thereof, including
without limitation Prior Agreement.

 

(k)            Amendment.
No amendment or other modification of this Agreement shall be effective unless made in writing and signed by the parties hereto.

 

(l)             Counterparts.
This Agreement and any agreement referenced herein may be executed simultaneously in two or more counterparts, each of which shall
be deemed an original but which together shall constitute one and the same instrument.

 

[SIGNATURES APPEAR ON FOLLOWING PAGE]

 

    15

     

    

 

IN WITNESS WHEREOF, the
Executive has hereunto set the Executive’s hand and, pursuant to the authorization from the Board, the Company has caused
these presents to be executed in its name on its behalf, all as of the day and year first above written.

 

	 	 	AZIYO BIOLOGICS, INC.
	 	 	 
	 	 	 
	 	By: 	/s/ Ronald Lloyd
	 	 	Name: Ronald Lloyd
	 	 	Title: President & CEO

 

 

		“EXECUTIVE”
	 	 
	 	 	/s/ Thomas Englese
	 	 	Thomas Englese

 

    S-1

     

    

 

EXHIBIT A

 

    

     

    

 

EXHIBIT B

 

GENERAL RELEASE

 

For
valuable consideration, the receipt and adequacy of which are hereby acknowledged, the undersigned does hereby release and forever
discharge the “Releasees” hereunder, consisting of Aziyo Biologics, Inc., and its partners, subsidiaries,
associates, affiliates, successors, heirs, assigns, agents, directors, officers, employees, representatives, lawyers, insurers,
and all persons acting by, through, under or in concert with them, or any of them, of and from any and all manner of action or
actions, cause or causes of action, in law or in equity, suits, debts, liens, contracts, agreements, promises, liability, claims,
demands, damages, losses, costs, attorneys’ fees or expenses, of any nature whatsoever, known or unknown, fixed or contingent
(hereinafter called “Claims”), which the undersigned now has or may hereafter have against the Releasees,
or any of them, by reason of any matter, cause, or thing whatsoever from the beginning of time to the date hereof.  The Claims
released herein include, without limiting the generality of the foregoing, any Claims in any way arising out of, based upon, or
related to the employment or termination of employment of the undersigned by the Releasees, or any of them; any alleged breach
of any express or implied contract of employment; any alleged torts or other alleged legal restrictions on Releasees’ right
to terminate the employment of the undersigned; and any alleged violation of any federal, state or local statute or ordinance
including, without limitation, Title VII of the Civil Rights Act of 1964, the Age Discrimination In Employment Act, the Americans
With Disabilities Act, and [__].1 Notwithstanding the foregoing, this general release (the “Release”)
shall not operate to release any rights or claims of the undersigned (i) to payments or benefits under Section 4(a) of
that certain Employment Agreement, effective as of [Ÿ], between Aziyo
Biologics, Inc. and the undersigned (the “Employment Agreement”), (ii) to payments or benefits
under any equity award agreement between the undersigned and the Company, (iii) with respect to Section 2(b)(iv) of
the Employment Agreement, (iv) to accrued or vested benefits the undersigned may have, if any, as of the date hereof under
any applicable plan, policy, practice, program, contract or agreement with the Company, (v) to any Claims, including claims
for indemnification and/or advancement of expenses arising under any indemnification agreement between the undersigned and the
Company or under the bylaws, certificate of incorporation or other similar governing document of the Company, (vi) to any
Claims which cannot be waived by an employee under applicable law or (vii) with respect to the undersigned’s right
to communicate directly with, cooperate with, or provide information to, any federal, state or local government regulator.

 

[IN ACCORDANCE WITH THE
OLDER WORKERS BENEFIT PROTECTION ACT OF 1990, THE UNDERSIGNED IS HEREBY ADVISED AS FOLLOWS:

 

(A)            THE
EXECUTIVE HAS THE RIGHT TO CONSULT WITH AN ATTORNEY BEFORE SIGNING THIS RELEASE;

 

(B)            THE
EXECUTIVE HAS TWENTY-ONE (21) DAYS TO CONSIDER THIS RELEASE BEFORE SIGNING IT; AND

 

(C)            THE
EXECUTIVE HAS SEVEN (7) DAYS AFTER SIGNING THIS RELEASE TO REVOKE THIS RELEASE, AND THIS RELEASE WILL BECOME EFFECTIVE UPON
THE EXPIRATION OF THAT REVOCATION PERIOD.]

 

 

 

1 Applicable state law references to be included.

 

    

     

    

 

The undersigned represents
and warrants that there has been no assignment or other transfer of any interest in any Claim which the Executive may have against
Releasees, or any of them, and the undersigned agrees to indemnify and hold Releasees, and each of them, harmless from any liability,
Claims, demands, damages, costs, expenses and attorneys’ fees incurred by Releasees, or any of them, as the result of any
such assignment or transfer or any rights or Claims under any such assignment or transfer.  It is the intention of the parties
that this indemnity does not require payment as a condition precedent to recovery by the Releasees against the undersigned under
this indemnity.

 

Notwithstanding anything
herein, the undersigned acknowledges and agrees that, pursuant to 18 USC Section 1833(b), the undersigned will not be held
criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made: (i) in
confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for
the purpose of reporting or investigating a suspected violation of law; or (ii) in a complaint or other document filed in
a lawsuit or other proceeding, if such filing is made under seal.

 

The undersigned agrees
that if the Executive hereafter commences any suit arising out of, based upon, or relating to any of the Claims released hereunder
or in any manner asserts against Releasees, or any of them, any of the Claims released hereunder, then the undersigned agrees to
pay to Releasees, and each of them, in addition to any other damages caused to Releasees thereby, all attorneys’ fees incurred
by Releasees in defending or otherwise responding to said suit or Claim.

 

The undersigned further
understands and agrees that neither the payment of any sum of money nor the execution of this Release shall constitute or be construed
as an admission of any liability whatsoever by the Releasees, or any of them, who have consistently taken the position that they
have no liability whatsoever to the undersigned.

 

IN WITNESS WHEREOF, the
undersigned has executed this Release this ____ day of ___________, ____.

 

 

 

 

    A-2Exhibit 10.10 

Execution
Version

 

EMPLOYMENT
AGREEMENT

 

THIS EMPLOYMENT AGREEMENT
(this “Agreement”), entered into as of September 30, 2020, is made by and between Aziyo Biologics, Inc.
(the “Company”) and Darryl Roberts, Ph.D. (the “Executive”) (collectively referred
to herein as the “Parties”).

 

WHEREAS, the Executive
is currently employed by the Company as its Executive Vice President, Operations and Product Development pursuant to the terms
of that certain Offer Letter by and between the Parties, dated as of April 25, 2016 (the “Prior Agreement”);

 

WHEREAS, the Company
is contemplating an initial public offering of its Class A common stock pursuant to an effective registration statement filed
under the Securities Act of 1933, as amended (the “IPO”);

 

WHEREAS, in connection
with the IPO, the Company desires to assure itself of the continued services of the Executive by engaging the Executive to perform
services under the terms hereof;

 

WHEREAS, the Executive
desires to provide services to the Company on the terms herein provided; and

 

WHEREAS, the Parties
desire to have this Agreement become effective, and supersede the Prior Agreement, as the date of the consummation of the IPO (the
 “Effective Date”).

 

NOW, THEREFORE, IT
IS HEREBY AGREED AS FOLLOWS:

 

1.            Employment
Period. Subject to the provisions for earlier termination hereinafter provided, the initial term of the Executive’s employment
hereunder shall be for a term (the “Initial Employment Period”) commencing on the Effective Date and
ending on the second anniversary of the Effective Date. The Initial Employment Period shall automatically be extended for successive
one-year periods (each, an “Extension Employment Period” and, together with the Initial Employment Period,
the “Employment Period”), unless either Party gives written notice of non-extension to the other no later
than ninety (90) days prior to the expiration of the then-applicable Employment Period, in which case Executive’s employment
will terminate at the end of the then-applicable Employment Period, subject to earlier termination as provided in Section 4
below.

 

2.            Terms
of Employment.

 

(a)            Position
and Duties.

 

(i)            Role
and Responsibilities. During the Employment Period, the Executive shall serve as Executive Vice President, Operations and Product
Development of the Company, and shall perform such employment duties as are usual and customary for such positions. The Executive
shall report directly to the Chief Executive Officer of the Company (or his or her designee). At the Company’s request, the
Executive shall serve the Company and/or its subsidiaries and affiliates in other capacities in addition to the foregoing, consistent
with the Executive’s position as Executive Vice President, Operations and Product Development of the Company. In the event
that the Executive, during the Employment Period, serves in any one or more of such additional capacities, the Executive’s
compensation shall not be increased beyond that specified in Section 2(b) hereof. In addition, in the event the Executive’s
service in one or more of such additional capacities is terminated, the Executive’s compensation, as specified in Section 2(b) hereof,
shall not be diminished or reduced in any manner as a result of such termination provided that the Executive otherwise remains
employed under the terms of this Agreement.

 

     

     

    

 

(ii)           Exclusivity.
During the Employment Period, and excluding any periods of vacation and sick leave to which the Executive may be entitled, the
Executive agrees to devote his or her full business time and attention to the business and affairs of the Company. Notwithstanding
the foregoing, during the Employment Period, it shall not be a violation of this Agreement for the Executive to: (A) serve
on boards, committees or similar bodies of charitable or nonprofit organizations or other companies, (B) fulfill limited teaching,
speaking and writing engagements, and (C) manage his or her personal investments, in each case, so long as such activities
do not individually or in the aggregate materially interfere or conflict with the performance of the Executive’s duties and
responsibilities under this Agreement; provided, that with respect to the activities in subclauses (A) and/or (B),
the Executive receives prior written approval from the Chief Executive Officer. Exhibit A of this Agreement sets forth
the board of directors or advisory boards on which the Executive currently serves.

 

(iii)          Principal
Location. During the Employment Period, the Executive shall perform the services required by this Agreement at the Company’s
principal offices located in Silver Spring, Maryland or such other location mutually agreed upon by the Company and the Executive
(the “Principal Location”), except for travel to other locations as may be necessary to fulfill the Executive’s
duties and responsibilities hereunder.

 

(b)          Compensation,
Benefits, Etc.

 

(i)            Base
Salary. During the Employment Period, the Executive shall receive a base salary (the “Base Salary”)
of $309,000 per annum. The Base Salary shall be reviewed annually by the Compensation Committee (the “Compensation
Committee”) of the Board of Directors of the Company (the “Board”) and may be increased
from time to time by the Compensation Committee in its sole discretion. The Base Salary shall be paid in accordance with the Company’s
normal payroll practices for executive salaries generally, but no less often than monthly. The Base Salary may be increased in
the Compensation Committee’s discretion, but not reduced, and the term “Base Salary” as utilized in this Agreement
shall refer to the Base Salary as so increased.

 

(ii)           Annual
Cash Bonus. In addition to the Base Salary, the Executive shall be eligible to earn, for each fiscal year of the Company ending
during the Employment Period, a discretionary cash performance bonus (an “Annual Bonus”) under the Company’s
bonus plan or program applicable to senior executives. The Executive’s target Annual Bonus shall be set at 45% of the Base
Salary actually paid for such year (the “Target Bonus”). The actual amount of any Annual Bonus shall
be determined by reference to the attainment of Company performance metrics and/or individual performance objectives, in each case,
as determined by the Compensation Committee, and may be greater or less than the Target Bonus (or zero). Subject to Section 4(a)(i) hereof,
payment of any Annual Bonus(es), to the extent any Annual Bonus(es) become payable, will be contingent upon the Executive’s
continued employment through the applicable payment date. The Company will pay any such bonus that has been duly earned and awarded
by the Board as soon as administratively possible following its approval by the Board and, in any event, no later than the later
of (i) the fifteenth day of the third month after the end of the Company’s fiscal year in which such bonus is earned
or (ii) March 15 following the calendar year in which such bonus is earned.

 

    	 	2	 

     

    

 

(iii)          Benefits.
During the Employment Period, the Executive (and the Executive’s spouse and/or eligible dependents to the extent provided
in the applicable plans and programs) shall be eligible to participate in and be covered under the health and welfare benefit plans
and programs maintained by the Company for the benefit of its employees from time to time, pursuant to the terms of such plans
and programs including any medical and dental insurance plans and programs. During the Employment Period, the Company shall provide
the Executive and the Executive’s eligible dependents with coverage under its group health plans. In addition, during the
Employment Period, Executive shall be eligible to participate in any retirement, savings and other employee benefit plans and programs
maintained from time to time by the Company for the benefit of its senior executive officers. Nothing contained in this Section 2(b)(iii) shall
create or be deemed to create any obligation on the part of the Company to adopt or maintain any health, welfare, retirement or
other benefit plan or program at any time or to create any limitation on the Company’s ability to modify or terminate any
such plan or program.

 

(iv)          Expenses.
During the Employment Period, the Executive shall be entitled to receive prompt reimbursement for all reasonable business expenses
incurred by the Executive in accordance with the policies, practices and procedures of the Company provided to employees of the
Company.

 

(v)           Fringe
Benefits. During the Employment Period, the Executive shall be eligible to receive such fringe benefits and perquisites as
are provided by the Company to its employees from time to time, in accordance with the policies, practices and procedures of the
Company, and shall receive such additional fringe benefits and perquisites as the Company may, in its discretion, from time-to-time
provide.

 

(vi)          Vacation.
During the Employment Period, the Executive shall be entitled to paid vacation in accordance with the plans, policies, programs
and practices of the Company applicable to its senior executives in effect from time to time, but in no event shall the Executive
be entitled to less than four (4) weeks of vacation per calendar year (pro-rated for any partial year of service).

 

3.            Termination
of Employment.

 

(a)          Death
or Disability. The Executive’s employment shall terminate automatically upon the Executive’s death during the Employment
Period. Either the Company or the Executive may terminate the Executive’s employment in the event of the Executive’s
Disability during the Employment Period. For purposes of this Agreement, “Disability” shall mean any
disability or incapacity that (i) renders Executive unable to substantially perform his duties hereunder for ninety (90) days
during any 12-month period or (ii) would reasonably be expected to render Executive unable to substantially perform his duties
for ninety (90) days during any 12-month period, in each case as determined by the Board in its good faith judgment.

 

(b)          Termination
by the Company. The Company may terminate the Executive’s employment during the Employment Period for Cause or without
Cause. For purposes of this Agreement, “Cause” shall mean the occurrence of any one or more of the following
events unless, to the extent capable of correction, the Executive fully corrects the circumstances constituting Cause within fifteen
(15) days after receipt of the Notice of Termination (as defined below):

 

(i)            Executive
performing his duties, in the good faith opinion of the Board, in a grossly negligent or reckless manner or with willful malfeasance;

 

    	 	3	 

     

    

 

(ii)           Executive
exhibiting habitual drunkenness or engaging in substance abuse;

 

(iii)          Executive
committing any material violation of any state or federal law relating to the workplace environment (including, without limitation,
laws relating to sexual harassment or age, sex or other prohibited discrimination) or any material violation of any Company policy;

 

(iv)          Executive
willfully failing or refusing to perform in the usual manner at the usual time those duties which he regularly and routinely performs
in connection with the business of the Company or such other duties reasonably related to the capacity in which he is employed
hereunder which may be assigned to him by the Board;

 

(v)           Executive
performing any material action when specifically and reasonably instructed not to do so by the Chairman or the Board;

 

(vi)          Executive
breaching Sections 7, 8 and 9 hereof;

 

(vii)         Executive
committing any fraud or using or appropriating for his or her personal use or benefit any funds, properties or opportunities of
the Company not authorized by the Board to be so used or appropriated; or

 

(viii)        Executive
being convicted of any felony or any other crime related to his employment or involving moral turpitude.

 

The Company shall not be entitled to terminate
Executive for Cause pursuant to clause (iii), (iv), (v) or (vi) unless the Company provides written notice stating in
reasonable detail the basis for termination and a fifteen (15) day opportunity to cure to Executive (unless (1) the Company
reasonably determines that providing such opportunity to cure to Executive is reasonably likely to have a material adverse effect
on its business, financial condition, results of operations, prospects or assets, (2) the facts and circumstances underlying
such termination are not able to be cured or (3) the Company has previously provided Executive an opportunity to cure the
applicable issue; in the case of (1), (2) or (3), the Company may terminate Executive without providing an opportunity to
cure).

 

(c)          Termination
by the Executive. The Executive’s employment may be terminated by the Executive for any reason, including with Good Reason
or by the Executive without Good Reason. For purposes of this Agreement, “Good Reason” shall mean the
occurrence of any one or more of the following events without the Executive’s prior written consent, unless the Company fully
corrects the circumstances constituting Good Reason (provided such circumstances are capable of correction) as provided below:

 

(i)            A
material reduction in the Executive’s job responsibilities and duties for the Company;

 

(ii)           A
material reduction in the Executive’s Base Salary; or

 

    	 	4	 

     

    

 

(iii)          a
requirement imposed by the Company on the Executive that Executive’s principal place of employment be anywhere other than
within a 50 mile radius of the Executive’s Principal Location, except for required travel on Company business to an extent
substantially consistent with Executive's business travel obligations, that, in any such case, is not cured by the Company within
fifteen (15) days after the Company’s receipt of written notice from the Executive of such event.

 

Notwithstanding the foregoing, the Executive
will not be deemed to have resigned for Good Reason unless (1) the Executive provides the Company with written notice setting
forth in reasonable detail the facts and circumstances claimed by the Executive to constitute Good Reason within sixty (60) days
after the date of the occurrence of any event that the Executive knows or should reasonably have known to constitute Good Reason,
(2) the Company fails to cure such acts or omissions within thirty (30) days following its receipt of such notice, and (3) the
effective date of the Executive’s termination for Good Reason occurs no later than sixty (60) days after the expiration of
the Company’s cure period.

 

(d)          Notice
of Termination. Any termination by the Company for Cause, or by the Executive for Good Reason, shall be communicated by a Notice
of Termination to the other parties hereto given in accordance with Section 13(d) hereof. For purposes of this Agreement,
a “Notice of Termination” means a written notice which (i) indicates the specific termination provision
in this Agreement relied upon, (ii) sets forth in reasonable detail the facts and circumstances claimed to provide a basis
for termination of the Executive’s employment under the provision so indicated and (iii) if the Date of Termination
(as defined below) is other than the date of receipt of such notice, specifies the termination date (which date shall be not more
than thirty (30) days after the giving of such notice). The failure by the Executive or the Company to set forth in the Notice
of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of the
Executive or the Company, respectively, hereunder or preclude the Executive or the Company, respectively, from asserting such fact
or circumstance in enforcing the Executive’s or the Company’s rights hereunder.

 

(e)          Termination
of Offices and Directorships; Return of Property. Upon termination of the Executive’s employment for any reason, unless
otherwise specified in a written agreement between the Executive and the Company, the Executive shall be deemed to have resigned
from all offices, directorships, and other employment positions if any, then held with the Company, and shall take all actions
reasonably requested by the Company to effectuate the foregoing. In addition, upon the termination of the Executive’s employment
for any reason, the Executive agrees to return to the Company all documents of the Company and its affiliates (and all copies thereof)
and all other Company or Company affiliate property that the Executive has in his or her possession, custody or control. Such property
includes, without limitation: (i) any materials of any kind that the Executive knows contain or embody any proprietary or
confidential information of the Company or an affiliate of the Company (and all reproductions thereof), (ii) computers (including,
but not limited to, laptop computers, desktop computers and similar devices) and other portable electronic devices (including,
but not limited to, tablet computers), cellular phones/smartphones, credit cards, phone cards, entry cards, identification badges
and keys, and (iii) any correspondence, drawings, manuals, letters, notes, notebooks, reports, programs, plans, proposals,
financial documents, or any other documents concerning the customers, business plans, marketing strategies, products and/or processes
of the Company or any of its affiliates and any information received from the Company or any of its affiliates regarding third
parties.

 

4.            Obligations
of the Company upon Termination. Upon a termination of the Executive’s employment for any reason, the Executive shall
be paid, in a single lump-sum payment on the date of the Executive’s termination of employment, the aggregate amount of the
Executive’s earned but unpaid Base Salary and accrued but unpaid vacation pay through the date of such termination (the “Accrued
Obligations”).

 

    	 	5	 

     

    

 

(a)          Without
Cause or For Good Reason. If the Executive’s employment with the Company is terminated during the Employment Period (x) by
the Company without Cause (other than by reason of the Executive’s death or Disability or due to the expiration of the Employment
Period) or (y) by the Executive for Good Reason (in either case, a “Qualifying Termination”), then
following the Executive’s Separation from Service (as defined below) (such date, the “Date of Termination”),
in each case, subject to and conditioned upon compliance with Section 4(d) hereof, in addition to the Accrued Obligations:

 

(i)            Cash
Severance. The Company shall continue to pay to the Executive the Executive’s Base Salary in effect on the Date of Termination
during the period beginning on the Date of Termination and ending on the 12-month anniversary of the Date of Termination (the “Severance
Period”) in installments in accordance with the Company’s regular payroll practices as of the Date of Termination;

 

(ii)           COBRA.
During the Severance Period, subject to the Executive’s valid election to continue healthcare coverage under Section 4980B
of the Internal Revenue Code and the regulations thereunder (together, the “Code”), the Company shall
continue to provide the Executive and the Executive’s eligible dependents with coverage under its group health plans at the
same levels and the same cost to the Executive as would have applied if the Executive’s employment had not been terminated
based on the Executive’s elections in effect on the Date of Termination (the “COBRA Payments”),
provided, however, that (A) if any plan pursuant to which such benefits are provided is not, or ceases
prior to the expiration of the period of continuation coverage to be, exempt from the application of Section 409A (as defined
below) under Treasury Regulation Section 1.409A-1(a)(5), or (B) the Company is otherwise unable to continue to cover
the Executive under its group health plans without incurring penalties (including without limitation, pursuant to Section 2716
of the Public Health Service Act or the Patient Protection and Affordable Care Act), then, in either case, an amount equal to each
remaining Company subsidy shall thereafter be paid to the Executive in substantially equal monthly installments over the continuation
coverage period (or the remaining portion thereof).

 

(iii)          Change
in Control. Notwithstanding the foregoing, if the Qualifying Termination occurs within the 12-month period following
a Change in Control, as defined in the Company’s 2020 Incentive Award Plan, as amended (and such Change in Control constitutes
a “change in control event” as defined in Treasury Regulations Section 1.409A-3(i)(5)), then in lieu of the foregoing
payments set forth in Section 4(a)(i), the Company shall pay to the Executive the sum of (x) 12-months of Executive’s
Base Salary in effect on the Date of Termination and (y) 1.0 times the Executive’s Target Bonus for the year in which
the Date of Termination occurs, during the Severance Period in installments in accordance with the Company’s regular payroll
practices as of the Date of Termination. In addition, unless otherwise explicitly set forth in any award agreement, any unvested
equity awards outstanding immediately prior to the Date of Termination shall automatically become fully vested and exercisable
(as applicable).

 

Notwithstanding the foregoing, it shall
be a condition to the Executive’s right to receive the amounts provided for in Sections 4(a)(i), 4(a)(ii) and 4(a)(iii) hereof
that the Executive execute and deliver to the Company an effective release of claims in substantially the form attached hereto
as Exhibit B (the “Release”) within twenty-one (21) days (or, to the extent required by law,
forty-five (45) days) following the Date of Termination and that the Executive not revoke such Release during any applicable revocation
period.

 

(b)          For
Cause, Without Good Reason or Other Terminations. If the Company terminates the Executive’s employment for Cause, the
Executive terminates the Executive’s employment without Good Reason, or the Executive’s employment terminates for any
other reason not enumerated in Sections 4(a) or 4(b) hereof, in any case, during the Employment Period, or if the Executive’s
employment with the Company is terminated due to the expiration of the Employment Period, then, in any case, the Company shall
pay to the Executive the Accrued Obligations in cash within thirty (30) days after the Date of Termination (or by such earlier
date as may be required by applicable law), and the Executive shall have no further rights hereunder.

 

    	 	6	 

     

    

 

(c)          Six-Month
Delay. Notwithstanding anything to the contrary in this Agreement, no compensation or benefits, including without limitation
any severance payments or benefits payable under Section 4 hereof, shall be paid to the Executive during the six (6)-month
period following the Executive’s “separation from service” from the Company (within the meaning of Section 409A,
a “Separation from Service”) if the Company determines that paying such amounts at the time or times
indicated in this Agreement would be a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code. If the payment
of any such amounts is delayed as a result of the previous sentence, then on the first day of the seventh month following the date
of Separation from Service (or such earlier date upon which such amount can be paid under Section 409A without resulting in
a prohibited distribution, including as a result of the Executive’s death), the Company shall pay the Executive a lump-sum
amount equal to the cumulative amount that would have otherwise been payable to the Executive during such period.

 

(d)          Exclusive
Benefits. Except as expressly provided in this Section 4 and subject to Section 5 hereof, the Executive shall not
be entitled to any additional payments or benefits upon or in connection with the Executive’s termination of employment.

 

5.            Non-Exclusivity
of Rights. Amounts which are vested benefits or which the Executive is otherwise entitled to receive under any plan, policy,
practice or program of or any contract or agreement with the Company at or subsequent to the Date of Termination shall be payable
in accordance with such plan, policy, practice or program or contract or agreement except as explicitly modified by this Agreement.

 

6.            Excess
Parachute Payments, Limitation on Payments.

 

(a)          Best
Pay Cap. Notwithstanding any other provision of this Agreement, in the event that any payment or benefit received or to be
received by the Executive (including any payment or benefit received in connection with a termination of the Executive’s
employment, whether pursuant to the terms of this Agreement or any other plan, arrangement or agreement) (all such payments and
benefits, including the payments and benefits under Section 4 hereof, being hereinafter referred to as the “Total
Payments”) would be subject (in whole or part), to the excise tax imposed under Section 4999 of the Code (the
 “Excise Tax”), then, after taking into account any reduction in the Total Payments provided by reason
of Section 280G of the Code in such other plan, arrangement or agreement, the cash severance payments under this Agreement
shall first be reduced, and the noncash severance payments hereunder shall thereafter be reduced, to the extent necessary so that
no portion of the Total Payments is subject to the Excise Tax but only if (i) the net amount of such Total Payments, as so
reduced (and after subtracting the net amount of federal, state and local income taxes on such reduced Total Payments and after
taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is
greater than or equal to (ii) the net amount of such Total Payments without such reduction (but after subtracting the net
amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which the Executive would
be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal
exemptions attributable to such unreduced Total Payments).

 

    	 	7	 

     

    

 

(b)          Certain
Exclusions. For purposes of determining whether and the extent to which the Total Payments will be subject to the Excise Tax,
(i) no portion of the Total Payments the receipt or enjoyment of which the Executive shall have waived at such time and in
such manner as not to constitute a “payment” within the meaning of Section 280G(b) of the Code shall be taken
into account; (ii) no portion of the Total Payments shall be taken into account which, in the written opinion of an independent,
nationally recognized accounting or consulting firm (the “Independent Advisors”) selected by the Company,
does not constitute a “parachute payment” within the meaning of Section 280G(b)(2) of the Code (including
by reason of Section 280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, no portion of such Total Payments
shall be taken into account which, in the opinion of the Independent Advisors, constitutes reasonable compensation for services
actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the “base amount”
(as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation; and (iii) the value of
any non-cash benefit or any deferred payment or benefit included in the Total Payments shall be determined by the Independent Advisors
in accordance with the principles of Sections 280G(d)(3) and (4) of the Code.

 

7.            Nondisclosure
and Nonuse of Confidential Information.

 

(a)          The
Executive’s employment creates a relationship of confidence and trust between the Company and the Executive with respect
to any information that is applicable to the business of the Company or the affiliates, any information that is otherwise used,
developed or obtained by the Company or any affiliate in connection with its business and any information that is applicable to
the business of any client, customer or other commercial partner of the Company or the affiliates, which may be made known to the
Executive or learned by the Executive in such context during the period of his employment with the Company. All such information,
whether oral or written, has commercial value in the business in which the Company is engaged and is referred to herein as “Confidential
Information”.

 

(b)          The
Company owns all right, title and interest in and to all Confidential Information. The Executive hereby assigns to the Company
all right, title and interest that he may have acquired or hereafter may acquire in all Confidential Information. The Executive
shall, at all times, both during the Employment Period and after the termination of the Employment Period, keep in confidence and
trust all Confidential Information and the Executive shall not use or disclose any Confidential Information except as may be necessary
in the ordinary course of performing his duties as an employee of the Company. Upon termination of the Employment Period, or at
any time upon the request of the Company before such termination, the Executive shall promptly (but no later than five (5) days
after the earlier of such termination or such request) destroy or deliver to the Company, at the Company’s option, all Confidential
Information in the Executive’s control or possession and a written certification of the Executive’s compliance with
such obligations.

 

(c)          the
Executive hereby represents and warrants to the Company that neither his performance of the terms of this Agreement nor his employment
with the Company will breach or conflict with any agreement, understanding, policy or other arrangement that he is a party to or
otherwise subject to or bound by (including, without limitation, any such agreement, understanding, policy or arrangement (i) relating
to nondisclosure or nonuse of proprietary information, knowledge or data or (ii) that otherwise assigns, licenses or otherwise
transfers any interest in or to any Company Innovation (as defined below) to person or entity other than the Company). The Executive
shall not disclose to the Company or otherwise use any confidential or proprietary information or material belonging to any other
person or entity.

 

(d)          Notice
of Immunity Under the Economic Espionage Act of 1996, as amended by the Defend Trade Secrets Act of 2016 (“DTSA”).
Notwithstanding any other provision of this Agreement:

 

(e)          the
Executive will not be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade
secret that: (A) is made: (1) in confidence to a federal, state, or local government official, either directly or indirectly,
or to an attorney; and (2) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is
made in a complaint or other document that is filed under seal in a lawsuit or other proceeding.

 

    	 	8	 

     

    

 

(f)           If
the Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, the Executive may disclose
the Company’s trade secrets to the Executive’s attorney and use the trade secret information in the court proceeding
if the Executive: (A) files any document containing the trade secret under seal; and (B) does not disclose the trade
secret, except pursuant to court order.

 

(g)          the
Executive shall (i) comply with all Company security policies and procedures as in force from time to time including, without
limitation, those regarding computer equipment, telephone systems, voicemail systems, facilities access, monitoring, key cards,
access codes, Company intranet, internet, social media and instant messaging systems, e-mail systems, document storage systems,
software licenses, data security, encryption, firewalls and passwords (the “Facilities and Information Technology Resources”);
(ii) not access or use any Facilities and Information Technology Resources except as authorized by the Company; and (iii) not
access or use any Facilities and Information Technology Resources in any manner after the termination of the Executive’s employment by
the Company, whether termination is voluntary or involuntary.

 

8.            Inventions
and Proprietary Rights.

 

(a)          the
Executive represents and warrants to the Company that he does not have any right, title or interest in or to any Innovation (as
defined below) applicable to the business of the Company or relating in any way to the Company’s business or demonstrably
anticipated research and development or business that were conceived, reduced to practice, created, derived, developed or made
by the Executive prior to the date hereof.

 

(b)          the
Executive hereby agrees promptly to disclose and describe to the Company, and the Executive hereby assigns to the Company all right,
title and interest in and to, each of the Innovations and all associated intellectual property rights that the Executive may solely
or jointly conceive, reduce to practice, create, derive, develop or make during the period of his employment with the Company that
(i) relate to the Company’s or any affiliate’s business or actual or demonstrably anticipated research or development,
(ii) were developed on any amount of the Company’s or any affiliate’s time or with the use of any of the Company’s
or any affiliate’s materials, equipment, supplies, facilities or information or (iii) resulted from any work that the
Executive performed for the Company or any affiliate (collectively, the “Company Innovations”). the Executive
further acknowledges and agrees that all Company Innovations, including, without limitation, any computer programs, programming
documentation, and other works of authorship, are “works made for hire” for purposes of the Company’s rights
under copyright laws and the Executive hereby assigns to the Company any and all right, title and interest that the Executive may
have acquired or may hereafter acquire in such Company Innovations. Any assignment of copyright hereunder includes all rights of
paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred to as “moral rights”
(collectively “Moral Rights”). To the extent that such Moral Rights cannot be assigned under applicable
law and to the extent the following is allowed by the laws in the various countries where Moral Rights exist, the Executive hereby
waives such Moral Rights and consents to any action of the Company and the affiliates that would violate such Moral Rights in the
absence of such consent. The Executive shall confirm any such waivers and consents from time to time as requested by the Company.
To the extent that any right, title or interest in or to any Company Innovation cannot be assigned by the Executive to the Company,
the Executive hereby grants to the Company an exclusive, royalty-free, transferable, irrevocable, worldwide license (with rights
to sublicense through multiple tiers of sublicensees) to practice such non-assignable right, title or interest. To the extent that
any right, title or interest in or to any Company Innovation can be neither assigned nor licensed by the Executive to the Company,
the Executive hereby irrevocably waives and agrees never to assert such non-assignable and non-licensable right, title or interest
against the Company, any affiliate or any of their successors in interest to such non-assignable and non-licensable rights.

 

    	 	9	 

     

    

 

(c)          the
Executive recognizes that Innovations and Confidential Information relating to his activities while working for the Company and
conceived, reduced to practice, created, derived, developed or made by the Executive, alone or with others, within six (6) months
after termination of his employment with the Company may have been conceived, reduced to practice, created, derived, developed
or made, as applicable, in significant part while employed by the Company. Accordingly, the Executive agrees that such Innovations
and Confidential Information shall be presumed to have been conceived, reduced to practice, created, derived, developed or made,
as applicable, during his employment with the Company and shall be assigned to the Company unless and until the Executive has established
the contrary by written evidence satisfying the clear and convincing standard of proof.

 

(d)          the
Executive shall perform, during and after his employment with the Company, all acts deemed necessary or desirable by the Company
to permit and assist the Company, at the Company’s expense, in obtaining and enforcing the full benefits, enjoyment, rights
and title throughout the world in the Confidential Information and Innovations assigned or licensed to, or whose rights are irrevocably
waived and shall not be asserted against, the Company and the affiliates under this Agreement. Such acts may include, but are not
limited to, execution of documents and assistance or cooperation (i) in the filing, prosecution, registration, and memorialization
of assignment of any applicable patents, copyrights, mask works or other applications, (ii) in the enforcement of any applicable
patents, copyrights, mask works, Moral Rights, trade secrets or other rights, and (iii) in other legal proceedings related
to the Confidential Information or Innovations.

 

(e)          In
the event that the Company is unable for any reason to secure the Executive’s signature to any document required to file,
prosecute, register, or memorialize the assignment of any patent, copyright, mask work or other applications or to enforce any
patent, copyright, mask work, Moral Right, trade secret or other right under any Confidential Information (including improvements
thereof) or any Innovations (including derivative works, improvements, renewals, extensions, continuations, divisionals, continuations
in part, continuing patent applications, reissues, and reexaminations thereof), the Executive hereby irrevocably designates and
appoints the Company and the Company’s duly authorized officers and agents as his agents and attorneys-in-fact to act for
and on his behalf and instead of the Executive (i) to execute, file, prosecute, register and memorialize the assignment of
any such application, (ii) to execute and file any documentation required for such enforcement and (iii) to do all other
lawfully permitted acts to further the filing, prosecution, registration, memorialization of assignment, issuance, and enforcement
of patents, copyrights, mask works, Moral Rights, trade secrets or other rights under the Confidential Information or Innovations,
all with the same legal force and effect as if executed by the Executive.

 

(f)           The
term “Innovations” means all processes, improvements, inventions (whether or not protectable under patent
laws), works of authorship, information fixed in any tangible medium of expression (whether or not protectable under copyright
laws), moral rights, mask works, trademarks, trade names, trade dress, trade secrets, know-how, ideas (whether or not protectable
under trade secret laws) and all other subject matter protectable under patent, copyright, moral right, mask work, trademark, trade
secret or other laws and includes, without limitation, all new or useful art, combinations, designs, developments, modifications,
derivative works, discoveries, formulae, techniques and all goodwill associated with any of the foregoing.

 

    	 	10	 

     

    

 

(g)          The
Executive hereby irrevocably consents to any and all uses and displays, by the Company and its affiliates, agents, representatives
and licensees, of the Executive’s name, voice, likeness, image, appearance, and biographical information in, on or in connection
with any pictures, photographs, audio and video recordings, digital images, websites, television programs and advertising, other
advertising and publicity, sales and marketing brochures, books, magazines, other publications, CDs, DVDs, tapes, and all other
printed and electronic forms and media throughout the world, at any time during or after the period of his employment by the Company,
for all legitimate commercial and business purposes of the Company (“Permitted Uses”) without further
consent from or royalty, payment, or other compensation to the Executive. the Executive hereby forever waives and releases the
Company and its directors, managing members, officers, employees and agents from any and all claims, actions, damages, losses,
costs, expenses, and liability of any kind, arising under any legal or equitable theory whatsoever at any time during or after
the period of his employment by the Company, arising directly or indirectly from the Company’s and its affiliates’,
agents’, representatives’ and licensees’ exercise of their rights in connection with any Permitted Uses.

 

9.            Non-Compete;
Non-Solicitation.

 

(a)          The
Executive acknowledges that, in the course of his employment with the Company and/or the Restricted Affiliates (as defined below),
he has become familiar, or will become familiar, with trade secrets and with other confidential information concerning the Company
and the Restricted Affiliates and that his services have been and will be of special, unique and extraordinary value to the Company
and the Restricted Affiliates. the Executive understands that the following restrictions may limit his ability to earn a livelihood
in a business similar to the business of the Company or any of the Restricted Affiliates, but he nevertheless believes that he
will receive sufficient consideration and other benefits as an equity holder and an employee of the Company and as otherwise provided
hereunder to clearly justify such restrictions which, in any event (given his education, skills and ability), the Executive does
not believe would prevent him from otherwise earning a living. The Executive further understands that the provisions of Sections
7 through 9, inclusive, are reasonable and necessary to preserve the business of the Company and the Restricted Affiliates. “Restricted
Affiliate” means any affiliate for which, during the twenty-four (24) month period preceding the Termination Date,
the Executive served as an officer or director or the Executive provided any material services.

 

(b)          In
light of Section 9(a), the Executive agrees that while the Executive is employed by the Company and for twelve (12) months
thereafter (such period, subject to automatic extension for an additional period equal to the period of any breach of the covenants
in this Section 9, shall be referred to herein as the “Non-Compete Period”), he shall not directly
or indirectly own, manage, operate, control, finance or invest in, participate in, consult with, render services for, act as an
officer, director, manager, partner, principal, agent, representative, contractor or advisor of or to, or in any manner engage
in or be associated with, hold any interest in, be employed by or represent any other business competing with the businesses or
the services or products of the Company or the Restricted Affiliates as such businesses and/or services or products exist or are
in the process of being formed, developed or acquired as of the Termination Date. Nothing herein shall prohibit the Executive from
being a passive owner of not more than one percent (1%) of the outstanding stock of any class of a corporation which is publicly
traded, so long as the Executive has no active participation in the business of such corporation.

 

(c)          Furthermore,
in light of Section 9(a), the Executive agrees that:

 

(i)            during
the Non-Compete Period, the Executive shall not directly or indirectly through another person or entity: (x) induce or attempt
to induce any employee or independent contractor of the Company or any Restricted Affiliate to leave the employ of or engagement
with the Company or such Restricted Affiliate, or in any way interfere with the relationship between the Company or any such Restricted
Affiliate, on the one hand, and any employee or independent contractor thereof, on the other hand; or (y) hire or engage any
person who was an employee or independent contractor of the Company until twelve months after such individual’s relationship
with the Company or any Restricted Affiliate has been terminated; and

 

    	 	11	 

     

    

 

(ii)           during
the Non-Compete Period, the Executive shall not directly or indirectly through another person or entity: (x) induce or attempt
to induce any customer (it being understood that the term “customer” as used throughout this Agreement includes any
person or entity that is receiving services from the Company or any Restricted Affiliate or that is directly or indirectly providing
or referring business for the Company or any Restricted Affiliate), supplier, independent contractor, licensee or other business
relation of the Company or any Restricted Affiliate to cease doing business with the Company or any Restricted Affiliate, or in
any way interfere with the relationship between any such customer, supplier, independent contractor, licensee or business relation,
on the one hand, and the Company or any Restricted Affiliate, on the other hand; or (y) solicit any customer of the Company
or any Restricted Affiliate in order to offer products or services similar to those offered by the Company or any Restricted Affiliate.

 

(d)          The
Executive shall inform any prospective or future employer of any and all restrictions contained in this Agreement and provide such
employer with a copy of such restrictions (but no other terms of this Agreement) prior to the commencement of that employment.

 

(e)          If,
at the time of enforcement of Section 9, a court holds that the restrictions stated herein are unreasonable under the circumstances
then existing, the Executive and the Company agree that the maximum period, scope or geographical area reasonable under such circumstances
shall be substituted for the stated period, scope or area so as to protect the Company to the greatest extent possible under applicable
law from improper competition.

 

(f)           In
the event of any breach or violation by the Executive of any of the restrictions contained in Section 9, any time period specified
herein shall abate during the time of any such breach or violation thereof and that portion remaining at the time of commencement
of any such breach or violation shall not begin to run until such breach or violation has been cured in all respects.

 

10.          Enforcement.
Because the Executive’s services are unique and because the Executive has access to Confidential Information and Company
Innovations, the parties hereto agree that monetary damages alone would be an inadequate remedy for any breach of this Agreement.
Therefore, in the event of a breach or threatened breach of this Agreement, the Company or its successors or assigns may, in addition
to other rights and remedies existing in their favor at law or in equity, apply to any court of competent jurisdiction for specific
performance and/or injunctive or other relief in order to enforce, or prevent any violations of, the provisions hereof (without
posting a bond or other security) or require the Executive to account for and pay over to the Company all compensation, profits,
moneys, accruals, increments or other benefits derived from or received as a result of any transactions constituting a breach of
the covenants contained in this Agreement, if and when final judgment of a count of competent jurisdiction is so entered against
the Executive. The rights and remedies of the Company under this Agreement are not exclusive of or limited by any other rights
or remedies which they may have, whether at law, in equity, by contract or otherwise, all of which shall be cumulative (and not
alternative). Without limiting the generality of the foregoing, the rights and remedies of the Company under this Agreement, and
the obligations and liabilities of the Executive under this Agreement, are in addition to their respective rights, remedies, obligations
and liabilities under the laws of unfair competition, laws relating to misappropriation of trade secrets and all other laws, rules and
regulations. No failure on the part of any person or entity to exercise any power, right, privilege or remedy under this Agreement,
and no delay on the part of any person or entity in exercising any power, right, privilege or remedy under this Agreement, shall
operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege
or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. No person or
entity shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this
Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly
executed and delivered on behalf of such person or entity; and any such waiver shall not be applicable or have any effect except
in the specific instance in which it is given.

 

    	 	12	 

     

    

 

11.          Representations.
The Executive hereby represents and warrants to the Company that (a) the Executive is entering into this Agreement voluntarily
and that the performance of the Executive’s obligations hereunder will not violate any agreement between the Executive and
any other person, firm, organization or other entity, and (b) the Executive is not bound by the terms of any agreement with
any previous employer or other party to refrain from competing, directly or indirectly, with the business of such previous employer
or other party that would be violated by the Executive’s entering into this Agreement and/or providing services to the Company
pursuant to the terms of this Agreement.

 

12.          Successors.

 

(a)          This
Agreement is personal to the Executive and, without the prior written consent of the Company, shall not be assignable by the Executive
otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable
by the Executive’s legal representatives.

 

(b)          This
Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

 

(c)            The
Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially
all of the business and/or assets of the Company to assume and agree to perform this Agreement in the same manner and to the same
extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, “Company”
shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees
to perform this Agreement by operation of law, or otherwise.

 

13.          Miscellaneous.

 

(a)           Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Maryland, without reference
to principles of conflict of laws. The captions of this Agreement are not part of the provisions hereof and shall have no force
or effect.

 

(b)          Compensation
Recovery Policy. Executive acknowledges and agrees that, to the extent the Company adopts any claw-back or similar policy pursuant
to the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, and any rules and regulations promulgated thereunder,
he or she shall take all action necessary or appropriate to comply with such policy (including, without limitation, entering into
any further agreements, amendments or policies necessary or appropriate to implement and/or enforce such policy with respect to
past, present and future compensation, as appropriate).

 

(c)          Whistleblower
Protections and Trade Secrets. Notwithstanding anything to the contrary contained herein, nothing in this Agreement prohibits
Executive from reporting possible violations of federal law or regulation to any United States governmental agency or entity in
accordance with the provisions of and rules promulgated under Section 21F of the Securities
Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of
state or federal law or regulation (including the right to receive an award for information provided to any such government agencies).
Furthermore, in accordance with 18 U.S.C. § 1833, notwithstanding anything to the contrary in this Agreement: (i) Executive
shall not be in breach of this Agreement, and shall not be held criminally or civilly liable under any federal or state trade secret
law (A) for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official
or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (B) for the disclosure
of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made
under seal; and (ii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law,
Executive may disclose the trade secret to Executive’s attorney, and may use the trade secret information in the court proceeding,
if Executive files any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant
to court order.

 

    	 	13	 

     

    

 

(d)          Notices.
All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party or by
registered or certified mail, return receipt requested, postage prepaid, addressed as follows:

 

If
to the Executive: at the Executive’s most recent address on the records of the Company.

 

If
to the Company:

 

Azyio Biologics, Inc.

12510 Prosperity Drive 

Suite 1-370 

Silver Spring, MD 20904 

Attention: Board of Directors

 

with a copy to:

 

Latham & Watkins LLP

885 Third Avenue 

New York, NY 10022-4802

Attn: [XXX]

 

or to such other address as either party
shall have furnished to the other in writing in accordance herewith. Notice and communications shall be effective when actually
received by the addressee.

 

(e)          Sarbanes-Oxley
Act of 2002. Notwithstanding anything herein to the contrary, if the Company determines, in its good faith judgment, that any
transfer or deemed transfer of funds hereunder is likely to be construed as a personal loan prohibited by Section 13(k) of
the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange
Act”), then such transfer or deemed transfer shall not be made to the extent necessary or appropriate so as not to
violate the Exchange Act and the rules and regulations promulgated thereunder.

 

(f)           Section 409A
of the Code.

 

(i)            To
the extent applicable, this Agreement shall be interpreted in accordance with Section 409A of the Code and Department of Treasury
regulations and other interpretive guidance issued thereunder (together, “Section 409A”). Notwithstanding
any provision of this Agreement to the contrary, if the Company determines that any compensation or benefits payable under this
Agreement may be subject to Section 409A, the Company shall work in good faith with the Executive to adopt such amendments
to this Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect),
or take any other actions, that the Company determines are necessary or appropriate to avoid the imposition of taxes under Section 409A,
including without limitation, actions intended to (i) exempt the compensation and benefits payable under this Agreement from
Section 409A, and/or (ii) comply with the requirements of Section 409A; provided, however,
that this Section 10(d) shall not create an obligation on the part of the Company to adopt any such amendment, policy
or procedure or take any such other action, nor shall the Company have any liability for failing to do so.

 

    	 	14	 

     

    

 

(ii)           Any
right to a series of installment payments pursuant to this Agreement is to be treated as a right to a series of separate payments.
To the extent permitted under Section 409A, any separate payment or benefit under this Agreement or otherwise shall not be
deemed “nonqualified deferred compensation” subject to Section 409A to the extent provided in the exceptions in
Treasury Regulation Section 1.409A-1(b)(4), Section 1.409A-1(b)(9) or any other applicable exception or provision
of Section 409A. Any payments subject to Section 409A that are subject to execution of a waiver and release which may
be executed and/or revoked in a calendar year following the calendar year in which the payment event (such as termination of employment)
occurs shall commence payment only in the calendar year in which the consideration period or, if applicable, release revocation
period ends, as necessary to comply with Section 409A. All payments of nonqualified deferred compensation subject to Section 409A
to be made upon a termination of employment under this Agreement may only be made upon Employee’s “separation from
service” from the Company (within the meaning of Section 409A, a “Separation from Service”).

 

(iii)          To
the extent that any payments or reimbursements provided to the Executive under this Agreement are deemed to constitute compensation
to the Executive to which Treasury Regulation Section 1.409A-3(i)(1)(iv) would apply, such amounts shall be paid or reimbursed
reasonably promptly, but not later than December 31 of the year following the year in which the expense was incurred. The
amount of any such payments eligible for reimbursement in one year shall not affect the payments or expenses that are eligible
for payment or reimbursement in any other taxable year, and the Executive’s right to such payments or reimbursement of any
such expenses shall not be subject to liquidation or exchange for any other benefit.

 

(g)          Severability.
The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other
provision of this Agreement.

 

(h)          Withholding.
The Company may withhold from any amounts payable under this Agreement such federal, state, local or foreign taxes as shall be
required to be withheld pursuant to any applicable law or regulation.

 

(i)           No
Waiver. The Executive’s or the Company’s failure to insist upon strict compliance with any provision of this Agreement
or the failure to assert any right the Executive or the Company may have hereunder, including, without limitation, the right of
the Executive to terminate employment for Good Reason pursuant to Section 3(c) hereof, shall not be deemed to be a waiver
of such provision or right or any other provision or right of this Agreement.

 

(j)           Entire
Agreement. As of the Effective Date, this Agreement constitutes the final, complete and exclusive agreement between the Executive
and the Company with respect to the subject matter hereof and replaces and supersedes any and all other agreements, offers or promises,
whether oral or written, by any member of the Company and its subsidiaries or affiliates, or representative thereof, including
without limitation Prior Agreement.

 

(k)          Amendment.
No amendment or other modification of this Agreement shall be effective unless made in writing and signed by the parties hereto.

 

(l)           Counterparts.
This Agreement and any agreement referenced herein may be executed simultaneously in two or more counterparts, each of which shall
be deemed an original but which together shall constitute one and the same instrument.

 

[SIGNATURES APPEAR ON FOLLOWING PAGE]

 

    	 	15	 

     

    

 

IN WITNESS WHEREOF, the
Executive has hereunto set the Executive’s hand and, pursuant to the authorization from the Board, the Company has caused
these presents to be executed in its name on its behalf, all as of the day and year first above written.

 

	 	AZIYO BIOLOGICS, INC.
	 	 
	 	 
	 	By:	/s/ Ronald Lloyd 
	 		Name:  Ronald Lloyd 
	 	 	Title: President & CEO 
	 	 	 
	 	 	 
	 	“ EXECUTIVE”
	 	 
	 	 
	 	 	/s/ Darryl Roberts
	 	 	Darryl Roberts, Ph.D.

 

    	 	S-1	 

     

    

 

EXHIBIT A

 

    	 		 

     

    

 

EXHIBIT B

 

GENERAL RELEASE

 

For
valuable consideration, the receipt and adequacy of which are hereby acknowledged, the undersigned does hereby release and forever
discharge the “Releasees” hereunder, consisting of Aziyo Biologics, Inc., and its partners, subsidiaries,
associates, affiliates, successors, heirs, assigns, agents, directors, officers, employees, representatives, lawyers, insurers,
and all persons acting by, through, under or in concert with them, or any of them, of and from any and all manner of action or
actions, cause or causes of action, in law or in equity, suits, debts, liens, contracts, agreements, promises, liability, claims,
demands, damages, losses, costs, attorneys’ fees or expenses, of any nature whatsoever, known or unknown, fixed or contingent
(hereinafter called “Claims”), which the undersigned now has or may hereafter have against the Releasees,
or any of them, by reason of any matter, cause, or thing whatsoever from the beginning of time to the date hereof.  The Claims
released herein include, without limiting the generality of the foregoing, any Claims in any way arising out of, based upon, or
related to the employment or termination of employment of the undersigned by the Releasees, or any of them; any alleged breach
of any express or implied contract of employment; any alleged torts or other alleged legal restrictions on Releasees’ right
to terminate the employment of the undersigned; and any alleged violation of any federal, state or local statute or ordinance
including, without limitation, Title VII of the Civil Rights Act of 1964, the Age Discrimination In Employment Act, the Americans
With Disabilities Act, and [__].1 Notwithstanding the foregoing, this general release (the “Release”)
shall not operate to release any rights or claims of the undersigned (i) to payments or benefits under Section 4(a) of
that certain Employment Agreement, effective as of [Ÿ], between Aziyo
Biologics, Inc. and the undersigned (the “Employment Agreement”), (ii) to payments or benefits
under any equity award agreement between the undersigned and the Company, (iii) with respect to Section 2(b)(iv) of
the Employment Agreement, (iv) to accrued or vested benefits the undersigned may have, if any, as of the date hereof under
any applicable plan, policy, practice, program, contract or agreement with the Company, (v) to any Claims, including claims
for indemnification and/or advancement of expenses arising under any indemnification agreement between the undersigned and the
Company or under the bylaws, certificate of incorporation or other similar governing document of the Company, (vi) to any
Claims which cannot be waived by an employee under applicable law or (vii) with respect to the undersigned’s right
to communicate directly with, cooperate with, or provide information to, any federal, state or local government regulator.

 

[IN ACCORDANCE WITH THE
OLDER WORKERS BENEFIT PROTECTION ACT OF 1990, THE UNDERSIGNED IS HEREBY ADVISED AS FOLLOWS:

 

(A)         THE
EXECUTIVE HAS THE RIGHT TO CONSULT WITH AN ATTORNEY BEFORE SIGNING THIS RELEASE;

 

(B)          THE
EXECUTIVE HAS TWENTY-ONE (21) DAYS TO CONSIDER THIS RELEASE BEFORE SIGNING IT; AND

 

(C)          THE
EXECUTIVE HAS SEVEN (7) DAYS AFTER SIGNING THIS RELEASE TO REVOKE THIS RELEASE, AND THIS RELEASE WILL BECOME EFFECTIVE UPON
THE EXPIRATION OF THAT REVOCATION PERIOD.]

 

 

[1]
Applicable state law references to be included.

 

    	 		 

     

    

 

The undersigned represents
and warrants that there has been no assignment or other transfer of any interest in any Claim which the Executive may have against
Releasees, or any of them, and the undersigned agrees to indemnify and hold Releasees, and each of them, harmless from any liability,
Claims, demands, damages, costs, expenses and attorneys’ fees incurred by Releasees, or any of them, as the result of any
such assignment or transfer or any rights or Claims under any such assignment or transfer.  It is the intention of the parties
that this indemnity does not require payment as a condition precedent to recovery by the Releasees against the undersigned under
this indemnity.

 

Notwithstanding anything
herein, the undersigned acknowledges and agrees that, pursuant to 18 USC Section 1833(b), the undersigned will not be held
criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made: (i) in
confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for
the purpose of reporting or investigating a suspected violation of law; or (ii) in a complaint or other document filed in
a lawsuit or other proceeding, if such filing is made under seal.

 

The undersigned agrees
that if the Executive hereafter commences any suit arising out of, based upon, or relating to any of the Claims released hereunder
or in any manner asserts against Releasees, or any of them, any of the Claims released hereunder, then the undersigned agrees to
pay to Releasees, and each of them, in addition to any other damages caused to Releasees thereby, all attorneys’ fees incurred
by Releasees in defending or otherwise responding to said suit or Claim.

 

The undersigned further
understands and agrees that neither the payment of any sum of money nor the execution of this Release shall constitute or be construed
as an admission of any liability whatsoever by the Releasees, or any of them, who have consistently taken the position that they
have no liability whatsoever to the undersigned.

 

IN WITNESS WHEREOF, the
undersigned has executed this Release this ____ day of ___________, ____.

 

 

 

 

    	 	A-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]